Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
SHH: 688336.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yanli Liu
- Employees
- 995
- Headquarters
- Shanghai, China
- IPO year
- 2020
- Market cap
- CN¥44.3B
- Website
- https://www.3s-guojian.com
Loading 688336…
Loading profile data…Frequently asked questions about 688336
What does Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS) do?
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. Its products include YISAIPU, a tumor necrosis factor inhibitor for rheumatism; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody injection; Cipte...
Where does 688336.SS trade?
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS) trades on the Shanghai Stock Exchange.
What sector is 688336.SS in?
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd?
Yanli Liu is the chief executive officer of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS).
Where is Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd headquartered?
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd is headquartered in China.
Does 688336.SS pay a dividend?
Yes — Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS) paid a trailing twelve-month dividend of CNY 0.12 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 688336.SS go public?
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS) completed its initial public offering in 2020.